Panel Discussion: Translating the Multiple Myeloma Endpoint Precedent into Solid Tumor Programs to Shorten the Path to Regulatory Acceptance

• Unpacking what secured MRD acceptance in myeloma and which elements transfer to solid tumors
• Addressing the sensitivity and heterogeneity challenges that make the solid tumor case fundamentally harder
• Sequencing the evidence generation so indications build on each other rather than starting from zero

Speakers:

David Weingeist

Senior Scientific Director, Global Oncology Diagnostics Leader

Johnson & Johnson

Paul Robbins

Vice President - Clinical Translation

Vividion Therapeutics

Yanwen Jiang

Distinguished Scientist

Genentech